Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

Eli Lilly’s next-generation, investigational weight-loss drug is just a few clicks away from being delivered to your door.

Eli Lilly has now issued a stark warning about the "counterfeit" and "black market" versions already being sold online ...

Last summer, the musician Angel Money wanted to lose weight ahead of a music video shoot. A friend of hers had been injecting herself with a peptide called retatrutide. Money was curious. “She handed ...

Behind the counter of a bodega in Brooklyn, a cashier casually rang up a tiny vial of a peptide the store advertised as retatrutide — an experimental weight-loss drug whose sale is generally ...

Test results on an unapproved peptide have revealed double the concentration listed on the label, prompting warnings from health professionals about "enormous" overdose risks. The vial of black-market ...

KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on ...

In late June 2026, a rumor spread that U.S. President Donald Trump had gained early and exclusive access to the pharmaceutical company Eli Lilly's retatrutide — a coveted obesity drug that is ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.